Demystifying Prostate Cancer Screening: A Step-by-Step Guide
While mammograms and smear tests are widely discussed, prostate screening remains a topic shrouded in uncertainty for many men. With Prostate Cancer Awareness Month approaching in March, it's crucial to shed light on this vital health check. We spoke with Mr Wissam Abou-Chedid, a consultant urological and robotic surgeon at Nuffield Health in Woking, Guildford, and Parkside in London, to clarify the entire screening process.
National Screening Programme Status
"As it stands in the UK, there's no national screening programme for prostate cancer," explains Abou-Chedid. "However, any male patient above the age of 50 can request a PSA check from their GP. Additionally, men aged 45 or older with a family history of prostate cancer are also eligible." This accessibility allows proactive health management despite the absence of a formal nationwide initiative.
Key Risk Factors for Prostate Cancer
Understanding risk factors is essential for early detection. Race plays a significant role, with Afro Caribbean men facing the highest risk—one in four will develop prostate cancer in their lifetime. For Caucasian men, the statistic is one in eight, and for Asian men, one in thirteen.
- Family history and genetics: Individuals with BRCA1 or BRCA2 gene mutations or relatives (father, brother, cousin, uncle) who have had prostate cancer are at increased risk.
- Age: The risk escalates with age, primarily affecting men over 50. Prostate Cancer UK notes that diagnoses peak between ages 70 and 74.
The Initial GP Consultation
When discussing prostate cancer concerns with a GP, the consultation typically involves:
- Risk assessment: Questions about age, race, and family history to evaluate individual risk levels.
- PSA test discussion: A detailed explanation of the prostate-specific antigen test, including its benefits and drawbacks.
Abou-Chedid emphasizes that GPs should outline both pros and cons. "A pro is early cancer detection, while a con might be anxiety or over-diagnosis of insignificant cancers that wouldn't require treatment." This balanced approach helps patients make informed decisions.
Understanding the PSA Test
The PSA test measures prostate-specific antigen levels in the blood, conducted at hospitals or GP surgeries by healthcare professionals. "PSA is a protein secreted by the prostate that can elevate if cancer is present," says Abou-Chedid. Results guide further investigations, such as MRI scans or biopsies.
Preparation for a PSA Test
Accurate results require proper preparation, as PSA levels can be influenced by various factors:
- Avoid ejaculation within 48 hours before the test, as it can artificially increase PSA by up to 20%.
- Limit activities like horse riding or prolonged cycling, which stress the pelvic area and may raise PSA levels.
- Address urinary tract infections (UTIs), as they can cause temporary PSA spikes.
Symptom-Free Screening
Prostate cancer is often asymptomatic in early to late stages, so waiting for symptoms like bone pain—which indicates spread—is not necessary. Abou-Chedid advises: "You don't need symptoms to request a PSA test; early detection is key."
Post-PSA Test Process
If PSA levels are elevated:
- Repeat test: A second PSA test is conducted after a few weeks to confirm results.
- MRI referral: If levels remain high, GPs refer patients to NHS Trusts for MRI scans to identify suspicious areas.
- Biopsy: Detected suspicious areas lead to biopsies, with results available in 7-10 days.
Results determine whether cancer is high-risk (requiring treatment) or low-risk (managed through active surveillance with regular PSA checks and MRIs).
Digital Rectal Examination (DRE) Controversy
While DRE can detect cancers in patients with normal PSA levels, recent guidelines from The British Association of Urological Surgeons (BAUS) recommend against routine use. "Many patients avoid screenings due to fear of this invasive exam," notes Abou-Chedid. "We encourage GPs to prioritize PSA checks and refer to specialists, who can decide on DRE if suspicion is high." This shift aims to reduce barriers to screening and promote early detection through less intimidating methods.
